ExonHit joins European Alzheimer's disease consortium
This article was originally published in Scrip
Executive Summary
ExonHit Therapeutics has joined the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer's disease (called PharmaCog – prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development).